Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs

Fig. 3

Second-generation ALK-TKI primary resistance models and therapeutic strategies after crizotinib resistance. (A) Second-generation ALK-TKI resistance model induced by SCC transformation. (B) Second-generation ALK-TKI resistance model induced by ALK compound mutation. (C) Prediction to the efficacy of sequential treatment of second-generation ALK-TKI. BBB, blood-brain barrier

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us